Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week. Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of brain cancer. DAY101 is a Phase 2-ready RAF inhibitor that also shows strong potential for other pediatric and adult indications. The company is co-founded by Chief Medical Officer Dr. Sam Blackman (who offered our May webinar) and Acting CEO Julie Grant from Canaan Partners. You can read more here. Please look for a […]
Read moreCurrently browsing: Community News
Jointly Sponsored Moonshot4Kids Congressional Briefing
CAC2 Members Jack’s Angels, Dragon Master Foundation, Max Cure Foundation, Children’s Cancer Cause, and National Brain Tumor Society joined together with others in the community through the DIPG Advocacy Group to hold the Moonshot4Kids Congressional Briefing on February 13 to raise awareness of H. Res. 114, which “Expressing support for the designation of the 17th day in May as “DIPG Awareness Day” to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.” You can read more about the Briefing and H. Res. 114 at CAC2 Blog Post #Moonshot4Kids. According to CAC2 […]
Read more
CAC2 Special Community Webinar–Vincristine Drug Shortage Update
Dr. Peter Adamson, Chair of the Children's Oncology Group (COG), shared information that COG has received along with a perspective on childhood cancer drug shortages, including the current situation with vincristine. We were pleased to join with the Alliance for Childhood Cancer to invite members of the two coalitions and the wider community this Community webinar. We offered this webinar so that the community could have a better understanding of the shortage, how to work with care providers, how to contact the FDA when problems arise from the shortage, and advocacy steps being taken. PUT_CHARACTERS_HERE Read more
STAR Act Co-Sponsor Map
Thanks to the many-faceted efforts in the childhood cancer community, the STAR Act has reached a tipping point (173 co-sponsors in the House of Representatives as of March 3, 2016). This is an important milestone in moving the bill through the legislative process. In March the focus is to push for even more co-sponsors, with a strong emphasis on Members who serve on the Energy & Commerce Committee. We want as many Members as possible supporting the bill, so that we can move the bill to a successful committee hearing. This map will help you locate your Representative: Hovering over or clicking each marker will […]
Read moreChildhood Cancer Congressional Caucus, Summit 2015 Notes
With thanks to CAC2 member Laurie Orloski for taking notes for us during this year’s Childhood Cancer Congressional Caucus Summit: The Congressional Childhood Cancer Caucus_2015_notes FINAL
Read morePediatric Cancer: Major Advances, Major Challenges – Notes from the 5th Annual Childhood Cancer Caucus
The Congressional Childhood Cancer Caucus Presents Pediatric Cancer: Major Advances, Major Challenges 5th Annual Childhood Cancer Caucus Friday, September 19, 2014 9:00 – 10:30 a.m. Congressional Auditorium, US Capitol Visitors Center Co-Chairs: Congressman Michael T. McCaul (R-TX) Congressman Chris Van Hollen (D-MD) Keynote speaker: Dr. Francis Collins, Director, National Institutes of Health (NIH) Speakers: Dr. Ronald DePinho, President, MD Anderson Cancer Center Dr. Amrit Ray, Chief Medical Officer, Johnson & Johnson – Janssen Pharmaceuticals Notes: by CAC2 Member Laurie Orloski Opening remarks Vickie Buenger, President of the Coalition of Childhood Cancer (CAC2) Vickie Buenger kicked off the Caucus by welcoming […]
Read moreNCI Meeting Scheduled for Fri. Feb 21
There will be a meeting next week at the National Cancer Institute (NCI) dedicated to pediatric cancer drug development. The National Cancer Institute (NCI) will hold its 64th Meeting of the Director’s Consumer Liaison Group (DCLG) on Friday, February 21, 2014 from 9:30 a.m. to 4:00 p.m. on the National Institutes of Health (NIH) Campus in Bethesda, MD. The meeting will focus on barriers to drug development in pediatric cancer research and will include participants from the pediatric cancer advocacy community, as well as private and public sector presenters. The panels will discuss the State of Pediatric Cancer Research, Potential […]
Read moreFrom the Congressional Childhood Cancer Caucus–Concerns about Daunorubicin Shortage
Link to Original on the Congressional Childhood Cancer Caucus website Nov 12, 2013 Caucus Asks Questions about the Ongoing Shortage of Daunorubicin WASHINGTON, D.C. – Out of concern over the ongoing shortage of daunorubicin, an essential therapy in the treatment of leukemia in children, Representatives McCaul and Van Hollen, the co-chairs of the Congressional Childhood Cancer Caucus, sent letters to the Food and Drug Administration (FDA) and Teva Pharmaceuticals, the sole remaining supplier of the drug. As of this summer, Teva Pharmaceuticals was the sole remaining supplier of the drug. Teva recently informed the FDA that the drug was in limited supply and that […]
Read more